Revive Therapeutics (FRA:31R) Common Stock: €30.17 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Revive Therapeutics Common Stock?

Revive Therapeutics FRA:31R +25.00% Common Stock is €30.17 Mil as of Mar. 2026. The stock has 2 warning signs investors should review.

Revive Therapeutics's quarterly common stock increased from Sep. 2025 (€29.47 Mil) to Dec. 2025 (€29.63 Mil) and increased from Dec. 2025 (€29.63 Mil) to Mar. 2026 (€30.17 Mil).

Revive Therapeutics's annual common stock increased from Jun. 2023 (€31.94 Mil) to Jun. 2024 (€32.20 Mil) but then declined from Jun. 2024 (€32.20 Mil) to Jun. 2025 (€30.26 Mil).

Revive Therapeutics Common Stock Historical Data

* Premium members only.

The historical data trend for Revive Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revive Therapeutics Common Stock Chart

Revive Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.82 31.85 31.94 32.20 30.26

Revive Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.61 30.26 29.47 29.63 30.17

Revive Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of €30.17 Mil mean?
Revive Therapeutics (FRA:31R) has a Common Stock of €30.17 Mil as of Mar. 2026. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Revive Therapeutics and its competitors.
Is Revive Therapeutics' Common Stock too high?
Revive Therapeutics' current Common Stock is €30.17 Mil.
How does Revive Therapeutics' Common Stock compare to ZTS?
Revive Therapeutics' Common Stock of €30.17 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Drug Manufacturers company?
A good Common Stock depends on the Drug Manufacturers industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Revive Therapeutics and its competitors. Revive Therapeutics's current Common Stock is €30.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revive Therapeutics stock overvalued right now?
Revive Therapeutics (FRA:31R) has a current Common Stock of €30.17 Mil. The current Common Stock is €30.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Revive Therapeutics (FRA:31R), the current Common Stock is €30.17 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Revive Therapeutics Business Description

Other Exchanges RVVTF:USARVV:Canada
Address 82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C 1P1
Revive Therapeutics Ltd is focused on the research, development, and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases. The firm's technology is being developed to fill the medical needs for diseases and disorders such as pain, inflammation, and wound care. The company is exploring the use of Bucillamine for the potential treatment of public health medical emergencies and rare inflammatory disorders. Revive is also advancing the development of Psilocybin-based therapeutics through various programs.